


integral molecular

Integral Molecular is a biotechnology company committed to addressing the unmet needs of drug discovery for the treatment and cure of human diseases that involve integral membrane proteins. **Membrane proteins**, which comprise nearly half of all existing drug targets, including G protein-coupled receptors and ion channels, are implicated in many major diseases, including AIDS, cancer, and rheumatoid arthritis.

Our Technologies


The Lipoparticle

- Biosensor binding kinetics
- Screening of MAb specificity and affinity
- Radio- and fluorescent-ligand binding assays
- HTS of ion channel blockers
- HTS of GPCR modulators
- Immunization or panning for MAbs
- Isolation of proteins for structural analysis



Shotgun Mutagenesis

- Structure-function relationships
- Mapping of MAb epitopes
- Mapping ligand binding pockets
- Identifying functional regions of proteins
- Investigating viral drug resistance
- Identifying signaling motifs
- Mapping drug binding sites
- Modeling and docking small molecule interactions
- Directed evolution in eukaryotic cells
- Identifying DNA/RNA active elements



Integral's technologies enable novel strategies for the discovery and development of drugs that target membrane proteins.

About Integral Integral Molecular was founded in 2001 and operates from the University City Science Center Research Park in Philadelphia. Integral's laboratories are well-equipped for a range of traditional and advanced membrane protein analyses. Integral has been working with pharmaceutical, biotechnology, and academic customers and collaborators since its founding, providing membrane protein-related products and services that advance its customers' scientific objectives. Integral has ongoing internal programs in the fields of infectious and inflammatory diseases.